Gene therapy for prostate cancer delivered by ovine adenovirus and mediated by purine nucleoside phosphorylase and fludarabine in mouse models

Gene Therapy

Volumn 9, Issue 12, 2002, Pages 759-768

  Voeks, D ^a   Martiniello Wilks, R ^a   Madden, V ^a   Smith, K ^b   Bennetts, E ^b   Both, G W ^b   Russell, P J ^a  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b CSIRO   (Australia)

Author keywords

Gene directed enzyme prodrug therapy; Ovine adenovirus; PC3 cells; RM1 cell line

Indexed keywords

ADENOVIRUS VECTOR; ANDROGEN; DRUG METABOLITE; FLUDARABINE PHOSPHATE; PRODRUG; PURINE NUCLEOSIDE PHOSPHORYLASE; VIRUS RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CLINICAL STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG IMPLANTATION; ENZYME ACTIVITY; GENE CONTROL; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSDUCTION; GROWTH INHIBITION; HUMAN; HUMAN ADENOVIRUS 5; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENCE; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; MALE; METHODOLOGY; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; ROUS SARCOMA ONCOVIRUS; SUBCUTANEOUS TISSUE TUMOR; TRANSGENE; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTION; VIRUS RECOMBINANT;

ADENINE; ANIMALS; AVIAN SARCOMA VIRUSES; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HUMANS; MALE; MASTADENOVIRUS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; PRODRUGS; PROSTATIC NEOPLASMS; PURINE-NUCLEOSIDE PHOSPHORYLASE; TRANSDUCTION, GENETIC; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; VIDARABINE PHOSPHATE;

ADENOVIRIDAE; ANIMALIA; DNA VIRUSES; HUMAN ADENOVIRUS; HUMAN ADENOVIRUS TYPE 5; MURINAE; ONCOVIRINAE; OVIS; ROUS SARCOMA VIRUS;

EID: 0036080550     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301698     Document Type: Article

References (55)

1. Cancer statistics 1996
2. Cancer statistics, 1998
3. Radical prostatectomy versus brachy-therapy for early-stage prostate cancer
4. Outcome profiles of locoregional disease after radical prostatectomy and radiotherapy
5. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer
6. Gene therapy for prostate cancer
7. Prostate cancer gene therapy
8. Gene therapy for prostate cancer. New perspectives on an old problem
9. Immunotherapy of prostate cancer in the Dunning rat model - Use of cytokine gene modified tumor vaccines
10. Molecular therapy with recombinant p53 adenovirus to an androgen-independent, metastatic human prostate cancer model
11. Antisense Bcl-2 oligodeoxy-nucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model
12. Combination gene therapy for liver metastasis of colon carcinoma in vivo
13. Prostate cancer gene therapy: Herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models
14. The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice
15. Cooperative binding of androgen receptors to two DNA sequences is required for androgen induction of the probasin gene
16. Bystander killing of melanoma cells using the human tyrosinase promoter to express the Escherichia coli purine nucleoside phosphorylase gene
17. Relative activity and specificity of promoters from prostate-expressed genes
18. In vivo gene therapy for prostate cancer: Preclinical evaluation of two different enzyme-prodrug systems delivered by identical adenovirus vectors
19. A transcriptional enhancer of the prostate-specific membrane antigen gene
20. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells
21. Targeted gene delivery by tropism-modified adenoviral vectors
22. The 'adenobody' approach to viral targeting: Specific and enhanced adenoviral gene delivery
23. Insertion of an RGD motif into the HI loop of adenovirus fiber protein alters the distribution of transgene expression of the systemically administered vector
24. Modification of an adenoviral vector with biologically selected peptides: A novel strategy for gene delivery to cells of choice
25. In situ gene therapy for adenocarcinoma of the prostate: A phase I clinical trial
26. Implication of cell kinetic changes during progression of human prostatic cancer
27. In vivo gene therapy of cancer with E. Coli purine nucleoside phosphorylase
28. Metabolism and metabolic actions of 6-methylpurine and 2-fluoroadenine in human cells
29. Tumor cell bystander killing in colonic carcinoma utilizing the Escherichia coli DeoD gene to generate toxic purines
30. Relative efficiency of tumor cell killing in vitro by two enzyme-prodrug systems delivered by identical adenovirus vectors
31. Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination
32. Oral tolerization to adenoviral proteins permits repeated adenovirus-mediated gene therapy in rats with pre-existing immunity to adenoviruses
33. Adenovirus vectors for gene delivery
34. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5
35. HCAR and MCAR: The human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses
36. Cell receptors involved in adenovirus entry
37. Ovine adenovirus vectors overcome pre-existing humoral immunity against human adenoviruses in vivo
38. Altered tropism of an ovine adenovirus carrying the fiber protein cell binding domain of human adenovirus type 5
39. Gene expression by atypical recombinant ovine adenovirus vectors during abortive infection of human and animal cells in vitro
40. Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted model
41. Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer
42. Induction of potent antitumor natural killer cell activity by herpes simplex virus thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer
43. Unusual features in the nucleotide sequence of a cDNA clone derived from the common region of avian sarcoma virus messenger RNA
44. Ovine adenovirus vectors promote efficient gene delivery in vivo
45. Gene therapy of cancer: Activation of nucleoside prodrugs with E. Coli purine nucleoside phosphorylase
46. An ovine adenovirus vector lacks transforming ability in cells that are transformed by AD5 E1A/B sequences
47. Ludarabine: Pharmacokinetics, mechanisms of action and rationales for combination therapies
48. Phase I clinical investigation of 9-beta-D-arabino-furanosyl-2-fluoroadenine 5′-monophosphate (NSC 312887), a new purine antimetabolite
49. Kinetic considerations for the regulation of adenosine and deoxyadenosine metabolism in mouse and human tissues based on a thymocyte model
50. Differences in deoxyadenosine metabolism in human and mouse lymphocytes
51. Construction and transfection of ovine adenovirus genomic clones to rescue modified viruses
52. Characterisation of Australian ovine adenovirus isolates
53. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy
54. Regio- and stereo-selective synthesis of 6-methyl-9(2-deoxy-β-D-erythropentofuranosyl)purine
55. Bladder cancer xenografts: A model of tumor cell heterogeneity